• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta Life Sciences Names Matthew McManus Chief Operating Officer

    1/6/22 4:05:00 PM ET
    $AZTA
    $BRKS
    Industrial Machinery/Components
    Technology
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    CHELMSFORD, Mass., Jan. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has appointed Matthew McManus Chief Operating Officer effective January 17th.  In this newly created role, Dr. McManus will oversee Life Sciences Products, Services, and all commercial operations of the business and will report directly to the CEO.

    "We are excited to have Matt join the Company as our COO," said Steve Schwartz, President and CEO of Azenta. "Matt brings decades of expertise in life sciences. His depth of knowledge and valuable perspective will enhance our leadership position in the markets we serve."

    Dr. McManus joins Azenta with over 25 years of experience in the life sciences industry and was most recently Senior Vice President and General Manager of the Molecular Diagnostics Division at Bio-Techne following its acquisition of Asuragen, where Dr. McManus was President and CEO.  Dr. McManus was previously the President and CEO of PrimeraDx.  He received his M.D. and Ph.D. from the University of Pennsylvania School of Medicine, his MBA from Boston College and his B.A. in Economics from College of the Holy Cross.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (NASDAQ:AZTA) from Brooks Automation, Inc, (NASDAQ:BRKS).

    In addition, the company operates the Semiconductor Solutions Group business, an industry-leading provider of semiconductor manufacturing automation and collaborative robotics solutions worldwide. On September 20, 2021, the Company announced the pending sale of this business to Thomas H. Lee Partners. Due to the pending divestiture, the Company began reporting the Semiconductor Solutions Group business as discontinued operations in its fiscal year-end earnings announcement. 

    Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

    INVESTOR CONTACTS:

    Sara Silverman

    Director, Investor Relations

    Azenta Life Sciences

    978.262.2635

    sara.silverman@azenta.com

    Sherry Dinsmore

    Azenta Life Sciences

    978.262.2400

    sherry.dinsmore@azenta.com 

    (PRNewsfoto/Brooks Automation)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-names-matthew-mcmanus-chief-operating-officer-301455816.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA
    $BRKS

    CompanyDatePrice TargetRatingAnalyst
    Azenta Inc.
    $AZTA
    1/5/2026$50.00In-line → Outperform
    Evercore ISI
    Azenta Inc.
    $AZTA
    12/19/2025$42.00 → $44.00Buy
    Needham
    Azenta Inc.
    $AZTA
    10/30/2025$38.00Hold → Buy
    Jefferies
    Azenta Inc.
    $AZTA
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    Azenta Inc.
    $AZTA
    7/22/2025$35.00Equal-Weight
    Stephens
    Azenta Inc.
    $AZTA
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    Azenta Inc.
    $AZTA
    4/4/2024$64.00Hold
    Jefferies
    Azenta Inc.
    $AZTA
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    $BRKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Azenta from In-line to Outperform and set a new price target of $50.00

    1/5/26 8:28:55 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Needham reiterated coverage on Azenta with a new price target

    Needham reiterated coverage of Azenta with a rating of Buy and set a new price target of $44.00 from $42.00 previously

    12/19/25 7:47:35 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Jefferies with a new price target

    Jefferies upgraded Azenta from Hold to Buy and set a new price target of $38.00

    10/30/25 7:56:09 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Cornog William L bought $189,884 worth of Common (7,000 units at $27.13), increasing direct ownership by 37% to 25,795 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/25/25 4:28:43 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: Director Malus Alan J bought $319,800 worth of Common (12,000 units at $26.65), increasing direct ownership by 238% to 17,035 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:07 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: President and CEO Marotta John bought $25,990 worth of Common (1,000 units at $25.99), increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:08 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    SEC Filings

    View All

    Azenta Inc. filed SEC Form 8-K: Other Events

    8-K - Azenta, Inc. (0000933974) (Filer)

    4/2/26 4:10:36 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Azenta Inc.

    SCHEDULE 13G/A - Azenta, Inc. (0000933974) (Subject)

    3/26/26 4:10:59 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    3/4/26 9:15:52 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

    BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado

    4/7/26 8:15:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference

    BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta p

    2/24/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Cornog William L

    4/A - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:21:57 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Director Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:12:14 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Cornog William L

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 5:47:58 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    Financials

    Live finance-specific insights

    View All

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

    BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

    2/4/26 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

    BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

    1/21/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BRKS
    Leadership Updates

    Live Leadership Updates

    View All

    Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

    BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado

    4/7/26 8:15:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    $AZTA
    $BRKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology